Ptc Therapeutics (PTCT)

May 13, 2025, 10:00 AM EDT - 19 hours ago

PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 12, 2025, 10:00 AM EDT - 1 day ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating PTC Therapeutics, Inc. (PTCT) And Encourages Investors to Connect

May 11, 2025, 10:00 AM EDT - 2 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating PTC Therapeutics, Inc. (PTCT) And Encourages Stockholders to Connect

May 9, 2025, 10:00 AM EDT - 4 days ago

PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 8, 2025, 10:00 AM EDT - 5 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against PTC Therapeutics, Inc. (PTCT) and Encourages Stockholders to Learn More About the Investigation

May 7, 2025, 10:00 AM EDT - 6 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages PTC Therapeutics, Inc. (PTCT) Investors to Inquire about Securities Investigation

May 6, 2025, 11:19 PM EDT - 7 days ago

PTC Therapeutics, Inc. (PTCT) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:01 PM EDT - 7 days ago

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 6, 2025, 1:00 PM EDT - 7 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against PTC Therapeutics, Inc. (PTCT) And Encourages Investors to Reach Out

May 5, 2025, 4:54 PM EDT - 8 days ago

Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal?

May 5, 2025, 7:00 AM EDT - 8 days ago

PTC518 PIVOT-HD Study Achieves Primary Endpoint

May 1, 2025, 4:30 PM EDT - 12 days ago

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 25, 2025, 9:00 AM EDT - 18 days ago

PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

Apr 24, 2025, 8:00 AM EDT - 19 days ago

PTC Therapeutics to Participate at Upcoming Investor Conferences

Apr 17, 2025, 8:00 AM EDT - 26 days ago

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results

Mar 31, 2025, 6:21 PM EDT - 6 weeks ago

Vaccine stocks fall following FDA resignation

BNTX MRNA NVAX PFE PCVX XBI

Mar 28, 2025, 9:31 AM EDT - 6 weeks ago

PTC Therapeutics Shares Fall After EU Drops Translarna Authorization

Mar 28, 2025, 9:20 AM EDT - 6 weeks ago

PTC Therapeutics says European Commission will remove muscle disorder drug

Mar 28, 2025, 9:00 AM EDT - 6 weeks ago

PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe

Mar 20, 2025, 8:00 AM EDT - 7 weeks ago

PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies

Mar 9, 2025, 9:47 AM EDT - 2 months ago

PTC Therapeutics: Upside In Rare Disease Innovation

Feb 27, 2025, 9:41 PM EST - 2 months ago

PTC Therapeutics, Inc. (PTCT) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:01 PM EST - 2 months ago

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 20, 2025, 8:00 AM EST - 2 months ago

PTC Therapeutics to Participate in Upcoming Investor Conferences

Feb 19, 2025, 7:00 AM EST - 2 months ago

PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia

Feb 13, 2025, 8:00 AM EST - 3 months ago

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results

Jan 13, 2025, 9:00 AM EST - 4 months ago

PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference

Dec 23, 2024, 8:00 AM EST - 5 months ago

PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 19, 2024, 8:00 AM EST - 5 months ago

PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia

Dec 2, 2024, 1:50 PM EST - 5 months ago

PTC Therapeutics Stock Soars on Novartis Licensing Agreement

Dec 2, 2024, 12:58 PM EST - 5 months ago

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program

NVS

Dec 2, 2024, 7:14 AM EST - 5 months ago

PTC Therapeutics signs up to $1.9 billion licensing deal with Novartis

NVS

Dec 2, 2024, 7:00 AM EST - 5 months ago

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

NVS

Nov 27, 2024, 7:51 AM EST - 5 months ago

PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs

Nov 27, 2024, 7:00 AM EST - 5 months ago

PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million